Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY:ABT)

133.24 -0.76 (-0.57%)
Official Closing Price Updated: 7:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
44 45 Next >
Better Buy: Johnson & Johnson vs. Abbott Laboratories
These two healthcare giants are among the safest stocks investors can buy right now. 
Via The Motley Fool
3 Top Healthcare Stocks Defying the Bear Market
These healthcare companies haven't been slowed by macroeconomic conditions. 
Via The Motley Fool
3 Food Processing Dividend Stocks That Could Benefit From Food Shortages Driven By Russia-Ukraine War
With global supply chain shortages impacting nearly every sector of the economy in the past two years, will global food shortages worsen? As the U.S. 
Via Benzinga
Got $1,000? 2 Bear Market Stocks to Jump On Right Now
Regardless of what the market does next, these top stocks have a much longer growth trajectory ahead. 
Via The Motley Fool
Investing $1,000 in the Current Market? Don't Overlook These 2 Winning Dividend Stocks
Just because the stock market is going haywire doesn't mean you have to sit on the sidelines. 
Via The Motley Fool
3 Reasons to Buy AbbVie Stock Right Now
The drugmaker has something to offer to all kinds of investors. 
Via The Motley Fool
Is This Dividend King a Buy Near Its 52-Week Low?
Shares of this medical device and diagnostics stock have slumped in 2022. 
Via The Motley Fool
2 Reasons to Buy DexCom, and 1 Reason to Sell
Do the potential benefits outweigh the risks? 
Via The Motley Fool
Edwards Life Sciences Stock Disaster Could Be Your Bounty
Heart disease equipment maker Edwards Life Sciences (NYSE: EW) stock has fallen (-46%) on the year after a disastrous reaction to its Q3 2022 earnings report. 
Via MarketBeat
Topics Death
Exposures COVID-19 Death
Targeting Autosomal Dominant Polycystic Kidney Disease With Novel Approaches
Approximately 160,000 individuals in the United States are diagnosed with polycystic kidney disease, and the global prevalence of the condition is estimated at between 4 million and 7 million people. 
Via Benzinga
Got $5,000? Buy These 3 Dividend Kings And Hold Them Forever
These healthcare companies should stay relevant for years as they continue to innovate with new products. 
Via The Motley Fool
Is DexCom a Good Healthcare Stock to Buy Now?
After rising about 50% in October, investors want to know if this stock still has any fuel in the tank. 
Via The Motley Fool
3 Dividend-Paying Stocks to Buy in November and Hold Forever
Adding these stocks to your portfolio could lead to a lifetime of passive income. 
Via The Motley Fool
This Groundbreaking Device Just Keeps Winning for Abbott Labs
Its continuous glucose monitor has proven immensely effective in helping type 2 diabetes patients. 
Via The Motley Fool
Intuitive Surgical Stock is Both a Legacy and Next-Gen Play
It’s hard to believe that the da Vinci Surgical System developed by Intuitive Surgical (NASDAQ: ISRG) is turning 22 years old since its U.S. Food and Drug 
Via MarketBeat
Topics Economy
Exposures COVID-19 Interest Rates Supply Chain
NYSE: ABT Investor Notice: Deadline on October 31, 2022 in Lawsuit Against Abbott Laboratories
San Diego, CA -- (SBWIRE) -- 10/31/2022 -- The Shareholders Foundation announced that a deadline is coming up on October 31, 2022 in the lawsuit filed for certain investors of Abbott Laboratories... 
Via SBWire
Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Abbott Laboratories (ABT) Investors of Class Action and to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
ABT MONDAY DEADLINE NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Abbott Laboratories Investors to Secure Counsel Before Important October 31 Deadline in Securities Class Action - ABT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
ABBOTT LABORATORIES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Abbott Laboratories - ABT
From Kahn Swick & Foti, LLC
Via Business Wire
Looking Into Abbott Laboratories's Recent Short Interest
Abbott Laboratories's (NYSE:ABT) short percent of float has fallen 16.33% since its last report. The company recently reported that it has 13.99 million shares sold short, which is 0.82% of all regular... 
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Latch, Azure, Abbott, and TuSimple and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022
Upgrades 
Via Benzinga
ABT FINAL DEADLINE: ROSEN, A TOP RANKED FIRM, Encourages Abbott Laboratories Investors to Secure Counsel Before Important October 31 Deadline in Securities Class Action - ABT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Is Abbott Laboratories Still a Good Dividend Stock to Buy?
Third-quarter results were less than encouraging on the surface, but what do they say about the road ahead for Abbott Laboratories? 
Via The Motley Fool
10 Dividend Kings That May Last Centuries
The following 10 Dividend Kings have increased their dividends for at least 50 consecutive years, and stand a good chance of increasing their dividends for another 50 years. 
Via Talk Markets
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Humanigen, Latch, Azure, and Abbott and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Amazon To $175? Plus JP Morgan Cuts Price Target On Meta Platforms
JP Morgan cut the price target on Amazon.com, Inc. (NASDAQ: AMZN) from $185 to $175. Amazon shares gained 2.2% to trade at $117.82 on Friday. 
Via Benzinga
Market Rallies, Hits Resistance As Treasury Yields Soar; Tesla, Netflix Are Big Movers: Weekly Review
Tesla hit lows on earnings while Netflix jumped. 
Via Investor's Business Daily
Want Passive Income? 3 Dividend Kings to Buy Right Now
These companies have what it takes to offer earnings growth over time. 
Via The Motley Fool
Bonds And Stocks Slide While Stock Earnings Split
The big headline of today was bonds including TLT and IEF extending their downward slide to fresh new lows of 2022. 
Via Talk Markets
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
44 45 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.